Figure 4

OS in the A24 (+) group related to immunological monitoring specific to each of the LY6K, TTK, and IMP3 peptides. In the 24(+) group, the in vitro cultured T cells were subjected to ELISPOT assays. The positive CTL responses specific to each of LY6K-, TTK-, and IMP3-peptides after the vaccination were observed in 63%, 45%, and 60% of the patients, respectively. The OS was compared between the patients with positive CTL response (+) and those with negative CTL response (−) for each peptide, the patients with positive CTL response specific to the LY6K-peptide revealed significantly better OS than those without CTL response (A). Similarly, the patients with positive CTL response specific to the TTK-peptide showed significantly better OS than those without CTL response (B). For IMP3, the patients with positive CTL response specific to the peptide tended to have better OS than those without CTL response, although the difference was not statistically significant (C).